Importantly, these data were confirmed using the interactive NCI Transcriptional Pharmacodynamics Workbench (NCI TPW), which allows for the exploration of gene expression and transcriptional response to different anticancer agents across a well characterized ensemble of cancer cell lines (https://tpwb.nci.nih.gov/GeneExpressionNCI60/index.html) [20]; indeed, as shown in Supplementary Figure S2, a significant induction over the basal expression of Oct-6 was detected in different cancer cell lineages treated with Dox (e.g., lung, melanoma, renal, and glioblastoma). The gene discussed is POU3F1; the disease is cancer.